EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Health‐Related Quality of Life and Preference‐Based Utility Index in People With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A National Registry Study

Maria H Hegelund iD, Thomas Bryrup, Esben H Henriksen iD, Christine Højte iD, Terese L Katzenstein iD, Majbritt Jeppesen iD, Tavs Qvist iD, Hanne V Olesen, Mette F Olsen iD, TransformCF Study Group

Pediatric Pulmonology · 2026-11 · 61 (11)

DOI: 10.1002/ppul.71905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 07.11.2026. Verfasst von Maria H Hegelund und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Danish Cystic Fibrosis Cohort. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quality of Life, Indoles, Pyrrolidines. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vertex Pharmaceuticals, Danish Cystic Fibrosis Patient Association, Capital Region of Denmark Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elexacaftor/tezacaftor/ivacaftor (ETI) has transformed cystic fibrosis (CF) by improving outcomes and survival. We aimed to evaluate changes in health‐related quality of life (HRQoL) and preference‐weighted utility index following ETI initiation in children and adolescents/adults with CF.

Methods

In this nationwide Danish CF cohort, HRQoL was assessed using age‐appropriate Cystic Fibrosis Questionnaire–Revised (CFQ‐R) versions before and after ETI initiation. Utility indices were derived from the adolescent/adult CFQ‐R using the CFQ‐R‐8D algorithm. Linear mixed‐effect models estimated changes from pre‐ETI to 6, 12, and 24 months.

Results

Among 387 participants (90 children, 297 adolescents/adults), children had higher pre‐ETI CFQ‐R scores across most domains compared to adolescents/adults. Compared to pre‐ETI, respiratory functioning improved in children at 6 months (5.1; 95% CI 1.2; 8.9) and 12 months (5.6; 95% CI 1.7; 9.6), but not at 24 months (3.5; 95% CI −1.5; 8.6). Adolescents/adults showed improvements at 6 months (12.6; 95% CI 10.2–14.9), 12 months (11.9; 95% CI 9.5–14.4), and 24 months (11.4; 95% CI 8.5–14.3) in respiratory functioning . In children, eating and digestion also improved, while other domains showed heterogeneous patterns with little change. Adolescents/adults improved across most domains except digestion . CFQ‐R utility score showed small increases.

Conclusion

ETI was associated with improvements across most HRQoL domains in adolescents/adults, while digestion remained unchanged. In contrast, digestion improved in children as well as respiratory functioning and eating . Modest psychosocial and utility changes likely reflect high pre‐ETI levels. The results underscore the need for age‐specific interpretation and refinement of HRQoL measures in the modulator era.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuality of LifeIndolesPyrrolidinesAminophenolsBenzodioxolesPyridinesQuinuclidinesPyrazolesChloride Channel AgonistsHumansAdolescentFemaleMaleChildRegistriesAdultDenmarkSurveys and QuestionnairesYoung AdultDrug Combinations

Stichwörter der Autor:innen

cystic fibrosiselexacaftor/tezacaftor/ivacaftorhealth‐related quality of lifepatient‐reported outcomes

Substanzen

IndolesPyrrolidinesAminophenolsBenzodioxoleselexacaftortezacaftorPyridinesQuinuclidinesDrug CombinationsPyrazoles

Autor:innen und Institutionen

  • The Danish Cystic Fibrosis Cohort.
  • Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Denmark.
  • Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Denmark.

ORCID-Profile: Maria H Hegelund, Esben H Henriksen, Christine Højte, Terese L Katzenstein, Majbritt Jeppesen, Tavs Qvist, Mette F Olsen

Förderung

  • Vertex Pharmaceuticals
  • Danish Cystic Fibrosis Patient Association
  • Capital Region of Denmark Research Fund

Zitieren

APA

Hegelund, M. H., Bryrup, T., Henriksen, E. H., Højte, C., Katzenstein, T. L., Jeppesen, M., Qvist, T., Olesen, H. V., Olsen, M. F., & TransformCF Study Group (2026). Health‐Related Quality of Life and Preference‐Based Utility Index in People With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A National Registry Study. Pediatric Pulmonology, 61(11). https://doi.org/10.1002/ppul.71905

Vancouver

Hegelund MH, Bryrup T, Henriksen EH, Højte C, Katzenstein TL, Jeppesen M, et al. Health‐Related Quality of Life and Preference‐Based Utility Index in People With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A National Registry Study. Pediatric Pulmonology. 2026;61(11). doi:10.1002/ppul.71905

BibTeX
@article{Hegelund2026,
  author = {Hegelund, Maria H and Bryrup, Thomas and Henriksen, Esben H and Højte, Christine and Katzenstein, Terese L and Jeppesen, Majbritt and Qvist, Tavs and Olesen, Hanne V and Olsen, Mette F and TransformCF Study Group, TransformCF Study Group},
  title = {Health‐Related Quality of Life and Preference‐Based Utility Index in People With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A National Registry Study},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {11},
  doi = {10.1002/ppul.71905}
}
Kostenlos starten →